LE180802 | Macular Degeneration Study

Help Medical Researchers

GET PAID 1900!

Enjoy Free WiFi & Food


Help us trial a new treatment for dry age-related macular degeneration (AMD) and juvenile onset macular degeneration, known as Stargardt disease (STGD).  Remuneration is based on completion of the in-house stay and all follow-up appointments.

Macular degeneration is the leading cause of major vision loss in Australia and can affect the ability to read, drive, recognise faces and perform activities that require detailed vision. Participating in this trial means you’ll be supporting world leading research into treatment for this condition. There are currently no approved treatments available for dry AMD or SGTD. 


5 day in-house stay

Inclusion Criteria

  • Healthy Males and Females, aged between 18 and 65
  • Females must be of Non-Childbearing Potential (either Surgically Sterile or Postmenopausal)
  • Body Mass Index (BMI) between 18 – 30 kg/m2
  • Must be free from any clinically significant illness or disease
  • Participants must be non-smokers (Have not used any nicotine containing products in the last 28 days)
  • Participants must not have a history any severe reactions to medications
  • Participants must not have a history of Retinal Macular Edema or Stargardt Disease

Spots are limited. Find out if you qualify today!

3 Appointments

Cohort In-House Appointment
Check-In Day-1 Dosing Day 1 Check-Out  Day 4 Day 5 Day 6 Day 8
5.1 29-Apr 30-Apr 03-May 04-May 05-May 08-May
5.2 06-May 07-May 10-May 11-May 12-May  15-May
Fix the following errors: